Research programme: cancer therapeutics - Bristol-Myers Squibb

Drug Profile

Research programme: cancer therapeutics - Bristol-Myers Squibb

Alternative Names: BMS-536924; BMS-554417; BMS-673675; BMS-695735; BMS-698769; BMS-738533; BMS-743816; BMS-794833; BMT 062789

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Aminopyridines; Benzimidazoles; Heterocyclic compounds; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Epidermal growth factor receptor antagonists; Insulin-like growth factor-I receptor antagonists; Mitogen-activated protein kinase inhibitors; Proto oncogene protein c met inhibitors; Receptor protein-tyrosine kinase antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 03 Dec 2016 Interim pharmacodynamics data from a preclinical studies in Lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 03 Nov 2010 Preclinical trials in Cancer in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top